ASCO defines meaningful

Share this article:

The American Society for Clinical Oncology is putting a definition to the FDA's term “clinically meaningful outcome.” BioCentury reports that the professional organization published its recommendations in the Journal of Clinical Oncology and developed guidelines for what constitutes "meaningful" in trials for pancreatic, breast, lung and colon cancers.

The group used overall survival as the primary endpoint and recommended a benchmark, such as establishing a period of 4 to 6 months, as the minimum median OS improvement for untreated, metastatic, triple-negative breast cancer.

The group also said the experimental treatments should not include a higher toxicity than current treatments.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.